Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.
Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality in immunosuppressed patients. Recent data suggest promising treatment results with dihydroxy-propoxymethyl-guanine (BW B759U; ganciclovir [GCV] ) (1, 3, 5, 7) . Since this drug is primarily eliminated by the kidneys, dosing regimens must be altered in patients with renal insufficiency (4); however, limited information is available concerning its use in patients requiring hemodialysis. The purpose of this study was to determine the pharmacokinetics of GCV in the treatment of CMV pneumonia in a heart transplant recipient requiring hemodialysis.
A 40-year-old woman required implantation of the Jarvik 7-70 artificial heart as a bridge to cardiac transplantation. Upon resolution of multiple complications, including acute renal failure, transplantation was performed 45 days later. Renal failure recurred postoperatively, and the patient required hemodialysis. One month after transplantation, the patient developed CMV pneumonia. GCV was administered at a dose of 1.25 mg/kg every 24 h following daily hemodialysis (creatinine clearance [CLCR]I, unmeasurable); the dose was adjusted based on concentrations in plasma to 2.5 mg/kg every 48 h following alternate-day hemodialysis (CLCR, 5 to 6 ml/min per 1.73 m2) and to 2.5 mg/kg every 72 h following every-third-day hemodialysis (CLCR, 13 ml/min per 1.73 m2).
GCV was provided by the Burroughs Wellcome Co., Research Triangle Park, N.C., as the sterile lyophilized salt. Doses of GCV were administered by constant infusion over 1 h. GCV levels were determined with plasma samples drawn at 0.25, 0.5, 2, 4, 8, and 12 h after the completion of the first infused dose and prior to hemodialysis. Simultaneous paired arterial and venous plasma samples were obtained at 0 min, at 1, 2, and 3 h during hemodialysis, and at the completion of the 4-h hemodialysis period. A final sample was drawn 2 h after hemodialysis. Hemodialysis was performed with a Cordis Dow 4000 Low Ultra Filtration dialyzer at a blood flow rate of 250 ml/min. For subsequent doses during the 6-week treatment period, peak GCV plasma samples were collected at 15 min after completion of the infusion and trough samples were collected just before the dose. GCV concentrations in plasma obtained after the first dose were assayed by high-performance liquid chromatogra-* Corresponding author. phy (4). The practical limit of assay sensitivity for GCV was 0.98 ,umol/liter. Each run was considered acceptable when the plasma controls were within 10% of the stated value. Subsequent peak and trough concentrations in plasma were determined by enzyme-linked immunosorbent assay (6) . This method is more rapid, and a good correlation (r = 0.951) exists between the two methods (6) .
Pharmacokinetic analysis of the data was performed using nonlinear, weighted (linear inverse variance of the assay weighting), least squares regression analysis of plasma concentration-time data fitted to a two-compartment model (2) . The plasma samples (n = 6) obtained with the first dose of GCV were used to calculate the volume of distribution, elimination rate constant, and total body clearance. GCV distribution was assumed to be the same for the patient both on and off hemodialysis. The 1.73 m2. The dialysis half-life (beta phase) was 4.0 h. The extraction coefficient for GCV averaged 0.29.
The correlation by regression analysis between measured and predicted GCV concentrations for the entire dosage period was strong (r = 0.92), with the slope of the line of best fit not far from one (1.4) and the intercept close to 0 (-3.2 ,umol).
Peak and trough GCV concentrations in plasma were maintained in the range consistent with those reported for patients with normal renal function (3). Efficacy was observed by clinical improvement and resolution of viremia. Neutropenia, a major side effect of GCV (3), did not occur in this patient. However, the benefit of GCV was temporary, with clinical deterioration and recurrent viremia occurring 3 months after discontinuation of therapy. Viral replication was suppressed with a second course of GCV therapy, and suppression was maintained with a weekly maintenance dose of 2.5 mg/kg. The patient died of multiple system organ failure 8.5 months after transplantation. Autopsy findings revealed no evidence of residual CMV disease.
As anticipated, the intrinsic elimination of GCV in this patient with renal insufficiency was markedly reduced. The half-life was 11 times greater than that previously reported for patients without renal insufficiency (4) . The total body clearance was approximately 5% of that reported for patients with normal renal function (4). GCV was removed by hemodialysis. The extraction coefficient averaged 0.29 during the first hemodialysis procedure, with a mean blood flow rate of 250 ml/min. A single dialysis procedure lowered concentrations in plasma by approximately 50%. The dialysis clearance was found to be 68.5 ml/min per 1.73 m2, which was seven times greater than that observed when the patient was not on hemodialysis.
The pharmacokinetic model, which incorporated the nonuniform repetitive dosing and changing clearance in the patient, reasonably predicted GCV concentrations throughout the 6-week treatment period. The correlation coefficient (r = 0.92) suggests the ability of the model to predict concentrations in plasma in patients with renal insufficiency and changing clearance resulting from hemodialysis.
When GCV is administered to patients with renal insufficiency, dosage modification is necessary. The experience with this patient suggests that GCV can be administered safely to patients with renal failure. We recommend that if GCV is used in patients with renal insufficiency, concentrations in plasma be monitored.
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